Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hyperpolarized 13-C-pyruvate Clear all
Recruiting No phase listed Observational

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03067467
View directory record Official record
Conditions
Brain Tumor Adult
Interventions
Hyperpolarized 13C-Pyruvate, Gadolinium
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Completed Phase 1 Interventional Results available

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

NCT03565367
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Interventions
Gadolinium, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Other · Drug · Procedure
Lead sponsor
Daniel M. Spielman
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 15, 2026, 1:22 PM EST
Suspended Phase 1 Interventional

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

NCT05873699
View directory record Official record
Conditions
Pancreatic Cyst
Interventions
Hyperpolarized 13-C-pyruvate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers

Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate

NCT03502967
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Hyperpolarized [1-13C] Pyruvate, Hyperpolarized [2-13C] Pyruvate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1Phase 2 Interventional

HP Pyruvate MRI in Cancers

NCT05697406
View directory record Official record
Conditions
Image, Warburg Effect, Tumors
Interventions
Hyperpolarized 13C-Pyruvate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

NCT06814587
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions
Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Terminated Phase 1 Interventional Results available

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

NCT04019002
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme
Interventions
Hyperpolarized Pyruvate (13C), Magnetic Resonance Spectroscopic Imaging (MRSI)
Drug · Procedure
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Suspended Phase 1 Interventional

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

NCT05866679
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Hyperpolarized 13-C-pyruvate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Months and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Terminated Phase 2 Interventional Results available

Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

NCT04565327
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Zhen Wang, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Nov 15, 2026, 1:22 PM EST
Withdrawn No phase listed Observational Accepts healthy volunteers

Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03759704
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Hyperpolarized 13CPyruvate
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1 Interventional

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

NCT04656431
View directory record Official record
Conditions
Primary CNS Lymphoma
Interventions
Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI)
Drug · Procedure
Lead sponsor
James Rubenstein
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 2 Interventional

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

NCT03933670
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging, MRI Ultrasound Fusion Guided Biopsy
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Completed Phase 1 Interventional

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

NCT02947373
View directory record Official record
Conditions
Pediatric Brain Tumors
Interventions
Hyperpolarized Pyruvate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Nov 15, 2026, 1:22 PM EST
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

NCT04589624
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Withdrawn Phase 2 Interventional

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

NCT03581500
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Level Greater Than Ten, Stage IIB Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1 Interventional

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

NCT06014905
View directory record Official record
Conditions
Meningioma
Interventions
Hyperpolarized carbon C 13 pyruvate, Magnetic Resonance Image (MRI), Saline
Drug · Procedure · Other
Lead sponsor
Charlie Wang, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1 Interventional

Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

NCT03830151
View directory record Official record
Conditions
Primary Brain Neoplasm
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Active, not recruiting Phase 2 Interventional

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

NCT04258462
View directory record Official record
Conditions
Benign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea
Drug · Procedure
Lead sponsor
Zhen Wang, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1 Interventional

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

NCT04540107
View directory record Official record
Conditions
Recurrent World Health Organization (WHO) Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
Drug · Procedure
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 15, 2026, 1:22 PM EST
Recruiting Phase 1 Interventional

Hyperpolarized Imaging in Diagnosing Participants With Glioma

NCT03739411
View directory record Official record
Conditions
Glioma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Radiation Therapy, Chemotherapy
Radiation · Procedure · Drug
Lead sponsor
Susan Chang
Other
Eligibility
19 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 15, 2026, 1:22 PM EST